Similar to colitis, the risk of hepatobiliary disorders in the anti-CTLA-4 antibodies group was speculated to be higher than PD-1/PD-L1 inhibitors (ROR025 1.3 and 1.3, respectively, Table 2). This evidence concerns the gene CTLA4 and colitis.